Spero TherapeuticsSPRO
About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Employees: 46
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,300% more call options, than puts
Call options by funds: $14K | Put options by funds: $1K
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0.15% more ownership
Funds ownership: 25.52% [Q1] → 25.68% (+0.15%) [Q2]
11% less funds holding
Funds holding: 53 [Q1] → 47 (-6) [Q2]
24% less capital invested
Capital invested by funds: $23.7M [Q1] → $18M (-$5.63M) [Q2]
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target | 451%upside $7 | Buy Reiterated | 3 Oct 2024 |
HC Wainwright & Co. Raghuram Selvaraju 56% 1-year accuracy 133 / 239 met price target | 451%upside $7 | Buy Reiterated | 6 Aug 2024 |
